Login / Signup

The role of flumazenil in generalised anxiety disorder: a pilot naturalistic open-label study with a focus on treatment resistance.

Alexander T GalloStephen AddisVlad MartynHishani RamanathanGrace K WilkersonKellie S BennettSean D HoodHans StampferGary K Hulse
Published in: Therapeutic advances in psychopharmacology (2023)
This study presents preliminary results for subcutaneous continuous low-dose FMZ's effectiveness and safety in GAD. The findings suggest that it is a safe, well-tolerated, and feasible treatment option in this group of patients. Future randomised control trials are needed in this field to determine the efficacy of this treatment.
Keyphrases
  • low dose
  • open label
  • clinical trial
  • newly diagnosed
  • randomized controlled trial
  • end stage renal disease
  • squamous cell carcinoma
  • high dose
  • phase ii study
  • rectal cancer
  • current status
  • locally advanced